Navigation Links
QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
Date:2/10/2010

tly available to the management of QRxPharma.  Forward-looking statements therefore speak only as of the date they are made, and we undertake no obligation to update publicly any of them in light of new information or future events.

By their very nature, forward-looking statements involve risks and uncertainties.  A number of important factors could therefore cause actual results to differ materially from those contained in any forward-looking statement.  Such factors include risks relating to the stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialisation of the Company's proposed products.

About QRxPharma

QRxPharma (ASX: QRX and OTCQX: QRXPY) is a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of therapies for pain management and central nervous system (CNS) disorders.  Based on a business strategy to expand the clinical utility and commercial value of marketed and/or existing compounds, QRxPharma's product portfolio includes both late and early stage clinical drug candidates with well-defined paths to regulatory approval and sales. The Company intends to directly commercialise its products in the US and seek strategic partnerships for worldwide markets.

QRxPharma's lead compound, MoxDuo™IR (Q8003IR), is in Phase 3 clinical development

and has successfully completed multiple comparative studies evaluating its efficacy and safety

against equianalgesic doses of morphine, oxycodone and Percocet® for the treatment of acute pain. Study results consistently demonstrate MoxDuo™IR's greater overall tolerability, achieving as good or better pain relief with substantially fewer incidences of moderate to severe side effects. The Company's preclinical and clinical pipeline includes other tec
'/>"/>

SOURCE QRxPharma Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
2. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
3. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
4. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
5. QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR
6. QRxPharma Limited Announces A$21.6 Million Fully Underwritten Capital Raising
7. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
8. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
9. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
10. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
11. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Immune Therapeutics, Inc. today announced ... for the compounding, packaging and distributing of its naltrexone tablets. ... the United States . KRS Global ... naltrexone tablets in various strengths for individual patients in response ...
(Date:1/23/2015)... Jan. 23, 2015  HyGreen, Inc., a leader in hand ... with RCA Medical, a subsidiary of Ascendis Health Limited, ... Each year, hundreds of millions of patients around ... organisms are transmitted from patient to patient via the ...
(Date:1/23/2015)... 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that ... of Lixte,s lead compound, LB‑100, is being conducted, has been ... S. Kovach , M.D., the founder and President of Lixte, ... at a single site. Accrual of patients, however, was slower ...
Breaking Medicine Technology:Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... Bacterin International Holdings, Inc. (NYSE Amex: ... bone graft material and antimicrobial coatings for medical applications, ... Concepts (AMC), the largest multi-specialty Orthopedic, Spine and Neuro ... The award gives Bacterin ,pre-approved, ready-access to ...
... PLANTATION, Fla. and PORTOLA VALLEY, Calif., Oct. 24, 2011 ... announced a collaboration for the process development and cGMP ... used in Phase I and Phase II clinical trials. ... is prostatectomy, or removal of the prostate," noted David ...
Cached Medicine Technology:Bacterin Awarded Approved Vendor Status for American Medical Concepts' Network of Hospitals in the Northwest U.S. 2Goodwin Biotechnology Announces a Collaboration with Spectros Corporation 2
(Date:1/22/2015)... LunaDress, with its top dressmaking technologies, has been ... business is showing its latest designs of wedding dresses and ... the company’s CEO, all the fresh new products are designed ... up to 80% off. All the clothes from LunaDress follow ...
(Date:1/22/2015)... January 22, 2015 Gabe’s Chemo Duck Program is ... the first app ever created for kids with cancer. The Chemo ... and devices, is filled with enjoyable games to help children of ... The free app helps to keep kids entertained, educated and at ...
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method put together ... by up to 30lbs in less than 12 weeks without ... Stevenson, prompting an investigative review. , “Our Incredible Bulk ... formula that allows the body to pack on a massive ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has ... View website of AngelWeddingDress.com to find more ... dresses online for a bridal party. AngelWeddingDress offers a ... them. Its maternity wedding dresses are specially designed for ...
(Date:1/22/2015)... 22, 2015 A new white paper ... and person-centeredness in the long-term care environment as well ... the continuum. The paper, “The Power of Person-Centeredness in ... and practices of the patient, resident and family experience ...
Breaking Medicine News(10 mins):Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3
... metabolic syndrome in strained unions, study finds , , THURSDAY, March ... unhappy marriage may be greater for women than men, a ... "strained" unions, those marked by arguing and being angry, were ... in the contentious relationships were more likely to develop high ...
... to Educate Americans on Value of Occupational Therapy and Important Role ... ... (Vocus) March 5, 2009 -- The American Occupational Therapy Association (AOTA) ... public about the scope and value of what experts are predicting ...
... 5 Medifast, Inc. (NYSE: MED ), ... today announced the appointment of John P. Daniels and ... Directors. With the addition of Mr. Daniels and ... comprised of fourteen members, ten of which are classified ...
... ANTONIO, March 5 A plentiful, inexpensive, topical compound ... Middle Eastern and African leishmaniasis as is the standard ... one of the findings of a research team from ... Thomas Jefferson University and led by Reza ...
... March 5 CorMatrix Cardiovascular, Inc., an Atlanta-based ... matrix (ECM Technology) biomaterial devices that harness the ... announced today that it has begun its expansion ... CorMatrix(R) ECM Technology(TM) in a patient undergoing cardiac ...
... Company suspends patient enrollment and contract manufacturing, ... 5 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc. (BMR.TSX), today announced ... existing cash resources. The plan is in response to ... Company,s ongoing evaluation of strategic alternatives. , As announced ...
Cached Medicine News:Health News:Bad Marriages Harder on Women's Health 2Health News:Bad Marriages Harder on Women's Health 3Health News:Nearing Centennial, Occupational Therapy Profession Launches New Brand 2Health News:Nearing Centennial, Occupational Therapy Profession Launches New Brand 3Health News:Medifast, Inc. Announces Appointment of Two Additional Independent Board Members 2Health News:Medifast, Inc. Announces Appointment of Two Additional Independent Board Members 3Health News:Medifast, Inc. Announces Appointment of Two Additional Independent Board Members 4Health News:The Texas Institute of Dermatology Team Finds Easy-to-Apply, Topical Drug Just as Good as Injectable Compound for a Disfigurating Skin Infection 2Health News:CorMatrix Cardiovascular Announces First European Implants of CorMatrix(R) ECM Technology(TM) 2Health News:Bradmer implements cash conservation plan 2Health News:Bradmer implements cash conservation plan 3
ThermalSeal RT (5mil) is Optically Clear for Real Time PCR and easy to apply. Works for all plates. Will not wrinkle in the freezer....
DMSO-resistant microplate sealing film...
Sealing tape featuring 3M adhesive technology. Opaque and strong. Prevents photo-degradation....
Aluminum Seal, Reflective, Bulk...
Medicine Products: